[spanish] [english]
ma dot
exposure® dermatological antiaging serum
with 10% argireline
anti aging serum

Exposure® Dermatological Antiaging Serum with 10% Argireline® is an hexapeptide based formulation that softens lines and wrinkles and restores optimum skin hydration in only 4 weeks. It is presented in convenient vegetable-based single dose capsules (for external use only).

Serum: Cyclopentasiloxane, dimethicone crosspolymer, ethylhexyl cocoate, c24-28 alkyl methicone, lecithin, glycolipids, aqua, acetyl hexapeptide-3, phenoxyethanol, parfum, benzyl salicylate, hexyl cinnamal.
External Coating: Corn starch modified, glycerin carrageenans (chondrus crispus), mica, disodium phosphate, ci 77891 (titanium dioxide), ci 77499 (iron oxides), ci 19149 (yellow 5) / silver colour.

Exposure® Dermatological Antiaging Serum with 10% Argireline® has been specifically formulated for the following indications:

  • To complement and maintain the optimum results obtained from medical aesthetic procedures such as muscle relaxing injections, dermal fillers and laser/ipl/radiofrequency.
    As a skincare daily routine, to help reduce existing expression lines and wrinkles, and to restore optimum hydration.
    To protect the skin from harmful environmental agents,

and with continuous use, to restore skin smoothness, elasticity and luminosity.

Exposure® Dermatological Antiaging Serum with 10% Argireline® uses a patented original formula. The single dose vegetable-based capsules, ensure the highest preservation and efficacy of its active ingredients:

  • argireline®: acetyl hexapeptide-3 is a unique ingredient with anti-wrinkle and anti-aging properties. It can show significant results in only 30 days of continuous use, as demonstrated in various scientific trials
  • ceramides: protective properties against harmful environmental factors, limiting loss of water and solutes. They play an important role in restoring skin optimum hydration
  • vegetal sphingolipids: intercellular communication properties which mediate in the collagen, elastin and GAGs (glycosaminoglycans) neo-synthesis

Suitable for all skin types.
To open: holding the capsule with your fingers, twist the small upper part until separated from the rest, and then press the lower part to release the serum. Apply the contents to desired areas with a gentle massage twice a day, or as directed by your Doctor. Best results usually appear after 4 weeks of continuous use.
Exposure® Dermatological Antiaging Serum with 10% Argireline® is suitable for use in face and body.

Topical use only. Do not apply to eyes, mucose membranes and/or open wounds.
Some patients experience breakouts any time they change their skin care regimen. Skin reactions to any new product, though rare, are likely to occur within the first few days of use. If any reaction occurs, wash the product off and discontinue use.

Prior history of sensitivity or allergic reaction to this product or any of its ingredients.

No systemic adverse reactions have been reported. In rare cases, hypersensitivity (localized contact dermatitis) may occur: gel application should be discontinued and the physician notified immediately.


Not tested on animals
Manufactured in the EC for Medical Aesthetics Ltd., London, UK.

1. Skin aging: postulated mechanisms and consequent changes in structure and function. Yaar M, Gilchrest BA. Clin Geriatr Med. 2001 Nov;17(4):617-30
2. Botulinum A exotoxin use in clinical dermatology. Carruthers A, Kiene K, Carruthers J. J Am Acad Dermatol. 1996 May;34(5 Pt 1):788-97.
3. Chemodenervation for facial dystonias and wrinkles. Harrison AR. Curr Opin Ophthalmol. 2003 Oct;14(5):241-5.
4. Using skin models to assess the effects of a protection cream on skin barrier function. zur Muhlen A, Klotz A, Weimans S, Veeger M, Thorner B, Diener B, Hermann M.
Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):167-75.
5. Cosmetic upper-facial rejuvenation with botulinum. Ellis DA, Tan AK. J Otolaryngol. 1997 Apr;26(2):92-6.
6. Application of a non-invasive method to study the moisturizing effect of formulations containing vitamins A or E or ceramide on human skin. Leonardi GR, Gaspar LR, Maia Campos PM. J Cosmet Sci. 2002 Sep-Oct;53(5):263-8.
7. Topical and systemic therapies for the aging face. Glaser DA, Rogers C. Facial Plast Surg Clin North Am. 2001 May;9(2):189-96, vii.
8. Topical agents for the aging face. Scully K. J Cutan Med Surg. 1999 Dec;3 Suppl 4:S1-
9. Topical agents used in association with cosmetic surgery. Draelos ZD. Semin Cutan Med Surg. 1999 Jun;18(2):112-8.
10. Skin rejuvenation regimens: a profilometry and histopathologic study. Rachel JD, Jamora JJ. Arch Facial Plast Surg. 2003 Mar-Apr;5(2):145-9.
11. New directions in skin care. Clark CP 3rd. Clin Plast Surg. 2001 Oct;28(4):745-50.
12. Facial skin rejuvenation. Holck DE, Ng JD. Curr Opin Ophthalmol. 2003 Oct;14(5):246-52.

©2006 Medical Aesthetics Ltd. London (UK) All rights reserved

Go Back
Email a friend